D
David D. Smith
Researcher at QIMR Berghofer Medical Research Institute
Publications - 167
Citations - 10386
David D. Smith is an academic researcher from QIMR Berghofer Medical Research Institute. The author has contributed to research in topics: Cancer & Survival rate. The author has an hindex of 51, co-authored 166 publications receiving 9129 citations. Previous affiliations of David D. Smith include Beckman Research Institute & Biogen Idec.
Papers
More filters
Journal ArticleDOI
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
Claudia M. Kowolik,Max S. Topp,Sergio Gonzalez,Timothy Pfeiffer,Simon Olivares,Nancy Gonzalez,David D. Smith,Stephen J. Forman,Michael C. Jensen,Laurence J.N. Cooper +9 more
TL;DR: In vivo, it is shown in vivo that adoptively transferred CD19RCD28(+) T cells show an improved persistence and antitumor effect compared with CD19R(+) T cells, implying that modifications to the CAR can result in improved therapeutic potential of CD19-specific T cells expressing this second-generation CAR.
Journal ArticleDOI
Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database
TL;DR: Although the impact of stage migration versus improved regional disease control cannot be separated on basis of the available information, the data provide support in favor of extended lymphadenectomy during potentially curative gastrectomy for gastric cancer.
Journal ArticleDOI
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
Julio Garcia-Aguilar,Oliver S. Chow,David D. Smith,Jorge E. Marcet,Peter A. Cataldo,Madhulika G. Varma,Anjali S. Kumar,Samuel Oommen,Theodore Coutsoftides,Steven R. Hunt,Michael J. Stamos,Charles A. Ternent,Daniel O. Herzig,Alessandro Fichera,Blase N. Polite,David W. Dietz,Sujata Patil,Karin Avila +17 more
TL;DR: Delivery of mFOLFOX6 after chemoradiation and before total mesorectal excision has the potential to increase the proportion of patients eligible for less invasive treatment strategies; this strategy is being tested in phase 3 clinical trials.
Journal ArticleDOI
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
Arti Hurria,Supriya G. Mohile,Ajeet Gajra,Heidi D. Klepin,Hyman B. Muss,Andrew E. Chapman,Tao Feng,David D. Smith,Can Lan Sun,Nienke A. de Glas,Harvey J. Cohen,Vani Katheria,Caroline Doan,Laura Zavala,Abrahm Levi,Chie Akiba,William P. Tew +16 more
TL;DR: This study externally validated a chemotherapy toxicity predictive model for older adults with cancer that should be considered when discussing the risks and benefits of chemotherapy with older adults.
Journal ArticleDOI
The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer
TL;DR: The survival of patients with well-differentiated thyroid cancer is adversely affected by lymph node metastases, and the optimum treatment for this cohort needs further delineation, as particular populations are at greater risk of recurrence and death.